News ArticleGlenmark Pharmaceuticals Posts Rs. 42,473 Million Revenue with 20% Like-for-Like Growth in Q2 FY27
Strong regional performances with 14% growth in India and 31% in North America core business complement multiple product launches including RYALTRIS® expansion
Glenmark Pharmaceuticals announced a consolidated revenue of Rs. 42,473 million for Q2 FY27, reflecting a like-for-like year-on-year growth of approximately 20%. The company showed robust regional growth, including a 14% rise in India and 31% in North America core business, supported by multiple new product launches and strategic expansions. EBITDA margin stood at 20.3%, with an adjusted PAT margin of 11.4%. Key product launches like RYALTRIS® expanded globally, with Brazil marking a significant milestone.
Glenmark Pharmaceuticals Limited
Investor Presentation
Glenmark Pharmaceuticals Limited reported consolidated revenue of Rs. 42,473 million for the second quarter of fiscal year 2026-27, marking a like-for-like year-on-year growth of about 20%. The company's growth was driven by robust performance across regions including India and North America, aided by multiple new product launches and a strong emerging markets presence.
The India formulation business grew approximately 14% year-on-year on a like-for-like basis in Q2 FY27, supported by expansion in key therapy franchises and oncology market advancements.
North America core business achieved around 31% year-on-year growth in Q2 FY27, excluding deferred out-licensing income. This growth followed the launch of four new products during the quarter and regulatory advancements at manufacturing facilities.
Europe segment showed a 6.2% increase in revenue with continued portfolio strengthening through new launches, including market traction for products like RYALTRIS® and WINLEVI®.
Emerging Markets revenue surged by 33.2%, led by expansion in dermatology and respiratory segments and launches like RYALTRIS® in Brazil.
Consolidated EBITDA reached Rs. 8,638 million with a margin of 20.3%, and adjusted profit after tax (PAT) stood at Rs. 4,852 million with an 11.4% margin for Q2 FY27.
Highlights
- Consolidated Q2 FY27 revenue of Rs. 42,473 million with ~20% like-for-like year-on-year growth.
- India formulation business grew ~14% year-on-year like-for-like in Q2 FY27.
- North America core business grew ~31% year-on-year net of deferred out-licensing income.
- Emerging markets revenue rose by 33.2% in Q2 FY27, driven by portfolio expansion and RYALTRIS® Brazil launch.
- EBITDA margin at 20.3% and adjusted PAT margin at 11.4% for the quarter.
- Global commercial presence of RYALTRIS® in 58 markets, with 10 additional launches planned soon.
Key Data Snapshot
What happened
- Glenmark Pharmaceuticals delivered a consolidated revenue of Rs. 42,473 million in Q2 FY27, registering a like-for-like 20% year-on-year growth.
- Strong regional revenue increases occurred with India at ~14%, North America core business at ~31%, and Emerging Markets at 33.2%.
- EBITDA margin was recorded at 20.3%, while adjusted PAT margin was 11.4%.
Key details
- North America revenue includes deferred out-licensing income for ISB 2001; net core business growth excluding this was ~31%.
- In India, growth was driven by core therapy franchises with expanding leadership in respiratory, dermatology, and oncology sectors.
- Europe delivered resilient performance with 6.2% revenue growth, supported by launches like RYALTRIS® and WINLEVI®.
- Emerging Markets saw portfolio expansion and strong sales, including a new launch of RYALTRIS® in Brazil.
Operational performance
- Four new products were launched in North America during Q2 FY27, with regulatory improvements in manufacturing facilities.
- Global innovative portfolio updates include further international expansion of RYALTRIS®, totaling 58 markets, with 10 upcoming launches.
- Winlevi® gained formulary status covering approximately 40% of the UK market potential, strengthening the European portfolio.
Business impact
- The company continues advancing its innovative oncology pipeline, expecting the first launch by the end of FY27.
- Multispecific oncology pipeline progress highlighted by Phase 1 data selected for presentation at the 2026 ASH Annual Meeting.
- Strategic product launches and regional growth suggest Glenmark is positioned for sustainable innovation-led business growth.
Highlights
- Consolidated Q2 FY27 revenue of Rs. 42,473 million with ~20% like-for-like year-on-year growth.
- India formulation business grew ~14% year-on-year like-for-like in Q2 FY27.
- North America core business grew ~31% year-on-year net of deferred out-licensing income.
- Emerging markets revenue rose by 33.2% in Q2 FY27, driven by portfolio expansion and RYALTRIS® Brazil launch.
- EBITDA margin at 20.3% and adjusted PAT margin at 11.4% for the quarter.
- Global commercial presence of RYALTRIS® in 58 markets, with 10 additional launches planned soon.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Source Information
More News on Investor Presentation
View allLatest corporate announcements and market updates in Investor Presentation.
Rubicon Research Limited Reports Nearly 40% Revenue Growth and 68% Profit Increase in Q2 FY26-27
Rubicon Research Limited posted significant financial growth for the quarter ended September 30, 2026, with revenue increasing by 39.9% year-on-year to ₹5,764 million and profit after tax rising 67.9% to ₹904 million. This performance includes the consolidation impact of its recent Arinna acquisition and reflects strong operational cash flows and product approvals.
Read Full Story
Inventurus Knowledge Solutions Reports Q2 FY27 Investor Presentation Highlighting AI-Driven Growth and Platform Innovation
Inventurus Knowledge Solutions Limited disclosed its investor presentation for the quarter and half-year ended September 30, 2026, emphasizing advancements in its AI-powered healthcare enablement platform, strategic execution plans, and ongoing partnerships to drive growth and optimize margins.
Read Full Story
Sai Life Sciences Reports 23% Revenue Growth in Q2 FY27 with ₹659 Crore Revenue Amid Strategic Expansion
Sai Life Sciences Limited announced a 23% year-over-year revenue growth to ₹659 crore for the second quarter of fiscal year 2027, supported by healthy performance in both its Contract Research (CRO) and Contract Development and Manufacturing Organization (CDMO) segments. The company reported an EBITDA margin of 28% and continued its capital expenditure with ₹621 crore invested in the first half of FY27 to expand capacity and capabilities.
Read Full Story
